Immuneering Corporation (IMRX)Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
5.16 USD
+0.05
(0.978%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 5.13 -0.03 (-0.030%) ⇩ (July 13, 2026, 6:49 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:19 a.m. EDT
The immediate catalyst is the robust Phase 3 data showing 17.3-month survival in pancreatic cancer trials, which has ignited significant speculative interest. Options flow confirms this sentiment, with traders aggressively buying calls at strikes like $7.50 while ignoring downside protection. However, the long-term outlook remains precarious due to the company's deep financial burn; free cash flow is negative $33 million, and the business relies entirely on future capital raises to fund development. While the current rally suggests the market believes the pipeline can succeed, the lack of profitability and reliance on external funding create a fragile foundation for sustained growth. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.086974 |
| AutoARIMA | 0.103059 |
| AutoETS | 0.103063 |
| MSTL | 0.115397 |
| MSTL_62 | 0.159725 |
| MSTL_113 | 0.176951 |
| MSTL_62_113 | 0.217376 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 6.93 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.139 |
| Excess Kurtosis | -0.52 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.806 |
| Market Cap | 333,838,560 |
| Forward P/E | -3.87 |
| Beta | 0.41 |
| Website | https://immuneering.com |
As of July 11, 2026, 4:19 a.m. EDT: Speculators are heavily positioned for upside, evidenced by massive open interest in $7.50 calls across multiple expirations compared to negligible put volume. This indicates a strong bullish bias despite the stock trading below its 200-day average.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.22541964 |
| Address1 | 245 Main Street |
| Address2 | Second Floor |
| All Time High | 33.99 |
| All Time Low | 1.0 |
| Ask | 6.34 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,919,790 |
| Average Daily Volume3 Month | 1,547,854 |
| Average Volume | 1,547,854 |
| Average Volume10Days | 1,919,790 |
| Beta | 0.405 |
| Bid | 5.16 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 3.192 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.16 |
| Current Ratio | 32.449 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 5.17 |
| Day Low | 4.936 |
| Debt To Equity | 1.806 |
| Display Name | Immuneering |
| Earnings Call Timestamp End | 1,762,808,400 |
| Earnings Call Timestamp Start | 1,762,808,400 |
| Earnings Timestamp | 1,778,848,200 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | -58,876,424 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.072 |
| Enterprise Value | 180,875,168 |
| Eps Current Year | -1.11286 |
| Eps Forward | -1.33286 |
| Eps Trailing Twelve Months | -1.06 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.8773 |
| Fifty Day Average Change | 0.28270006 |
| Fifty Day Average Change Percent | 0.057962414 |
| Fifty Two Week Change Percent | 22.541964 |
| Fifty Two Week High | 10.08 |
| Fifty Two Week High Change | -4.92 |
| Fifty Two Week High Change Percent | -0.48809525 |
| Fifty Two Week Low | 2.9 |
| Fifty Two Week Low Change | 2.2599998 |
| Fifty Two Week Low Change Percent | 0.7793102 |
| Fifty Two Week Range | 2.9 - 10.08 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,651,800,000 |
| Float Shares | 49,435,285 |
| Forward Eps | -1.33286 |
| Forward P E | -3.8713741 |
| Free Cashflow | -33,193,532 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 55 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.13475999 |
| Held Percent Institutions | 0.47737998 |
| Implied Shares Outstanding | 64,697,402 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Immuneering Corporation |
| Market | us_market |
| Market Cap | 333,838,560 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_308350677 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -54,439,660 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 330,603,724 |
| Number Of Analyst Opinions | 7 |
| Open | 5.07 |
| Operating Cashflow | -49,697,400 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 500 8080 |
| Post Market Change | -0.029999733 |
| Post Market Change Percent | -0.5813902 |
| Post Market Price | 5.13 |
| Post Market Time | 1,783,982,977 |
| Previous Close | 5.11 |
| Price Eps Current Year | -4.636702 |
| Price Hint | 2 |
| Price To Book | 1.6165414 |
| Profit Margins | 0.0 |
| Quick Ratio | 31.501 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.28571 |
| Region | US |
| Regular Market Change | 0.0499997 |
| Regular Market Change Percent | 0.978468 |
| Regular Market Day High | 5.17 |
| Regular Market Day Low | 4.936 |
| Regular Market Day Range | 4.936 - 5.17 |
| Regular Market Open | 5.07 |
| Regular Market Previous Close | 5.11 |
| Regular Market Price | 5.16 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 703,304 |
| Return On Assets | -0.27885 |
| Return On Equity | -0.43839002 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 64,697,402 |
| Shares Percent Shares Out | 0.2323 |
| Shares Short | 15,027,581 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 12,724,428 |
| Short Name | Immuneering Corporation |
| Short Percent Of Float | 0.3061 |
| Short Ratio | 6.99 |
| Source Interval | 15 |
| State | MA |
| Symbol | IMRX |
| Target High Price | 30.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 17.85714 |
| Target Median Price | 17.0 |
| Total Cash | 156,693,616 |
| Total Cash Per Share | 2.422 |
| Total Debt | 3,730,204 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.06 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.606625 |
| Two Hundred Day Average Change | -0.44662523 |
| Two Hundred Day Average Change Percent | -0.07966027 |
| Type Disp | Equity |
| Volume | 703,304 |
| Website | https://immuneering.com |
| Zip | 2,142 |